UCD0068

UCD0068 shows weak affinity for the serotonin 5-HT_2A receptor (K_i = 890 nM). The drug's affinity for this receptor was 166-fold lower than that of LSD. UCD0068 acts as a moderate-to-high efficacy partial agonist of the serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors. Its EC₅₀Tooltip half-maximal effective concentration and E_maxTooltip maximal efficacy values at these receptors were found to be 104 nM (60%) at the serotonin 5-HT_2A receptor, 9.24 nM (61%) at the serotonin 5-HT_2B receptor, and 176 nM (89%) at the serotonin 5-HT_2C receptor. The drug was 188-fold, 17-fold, and 283-fold less potent as an agonist of these receptors than LSD, respectively. Hence, it is a relatively selective serotonin 5-HT_2B receptor agonist.

In contrast to LSD and another partial lysergamide known as UCD0120 (dides-B,C-LSD), UCD0068 failed to induce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. As such, UCD0068 would be expected to be non-hallucinogenic in humans.

The chemical synthesis of UCD0068 has been described. A variety of other deconstructed analogues of LSD along with UCD0068 have also been described.

UCD0068 was first described in the scientific literature by Zenichi Horii and colleagues by 1967. Subsequently, it was studied and described in greater detail by David E. Olson and colleagues at the University of California, Davis in 2026.